ASCLETIS PHARMA INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.36 HKD | +3.82% |
|
+7.09% | -6.85% |
| Apr. 03 | Ascletis Discontinues Trials of FXR Agonist for Biliary Cholangitis, NASH and Hepatitis B Virus | MT |
| Apr. 03 | Ascletis Pharma Inc. Announces Strategic Decisions on FXR Agonist ASC42 | CI |
ETFs positioned on Ascletis Pharma Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.78% | 4 M€ | -27.92% | ||
| 0.00% | 34 M€ | +2.22% | - |
Ascletis Pharma Inc is a China-based investment holding company principally engaged in the research, development, production, marketing and sales of pharmaceutical products. The Company mainly focuses on viral diseases, non-alcoholic steatohepatitis (NASH) and oncology fields. Viral diseases pipeline includes Ritonavir, Ravidasvir, Danoprevir and others. NASH pipeline includes ASC40, ASC41, ASC42 and others. Oncology pipeline includes ASC60, ASC61 and others.
Sector
Pharmaceuticals
Calendar
2024-08-18
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.259
CNY
Average target price
2.752
CNY
Spread / Average Target
+118.65%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -6.85% | 169M | |
| -4.72% | 87.31B | |
| +2.63% | 40.86B | |
| -21.76% | 29.36B | |
| +58.56% | 24.49B | |
| -14.78% | 17.31B | |
| -18.49% | 11.62B | |
| -15.61% | 11.31B | |
| -44.02% | 11.26B | |
| +5.17% | 8.31B |
- Stock Market
- Equities
- 1672 Stock
- Funds and ETFs Ascletis Pharma Inc.
